JC2-11

• UNSPSC Description:

  JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1[1].

• Target Antigen:

  AIM2; NOD-like Receptor (NLR)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/jc2-11.html

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  COC1=CC(/C=C/C(C2=CC(F)=C(C=C2)OC)=O)=CC=C1O

• Molecular Weight:

  302.30

• References & Citations:

  [1]Lee G, et al, JC2-11, a benzylideneacetophenone derivative, attenuates inflammasome activation. Sci Rep. 2022 Dec 28;12(1):22484.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  937820-89-8